Tirzepatide Achieves Quarterly Sales Exceeding $1.4 Billion, Up 44% Quarter-over-Quarter

Nov 02, 2023 19:36 CST Updated 19:36

Eli Lilly

Global Pharmaceutical R&D and Production Company

On November 2, Eli Lilly and Company released its financial report for the first three quarters of 2023.ThreeQuarterTotal Revenue247.71billion dollars, a year-on-year increase of 17%.

Among which, the revenue in the third quarter was 9.499 billion US dollars, increasing by 37% year-on-year. The main driving force originated fromGLP-1R/GIPR Dual AgonistMounjaro（Tirzepatide, Tirzepatide）Rapid Scaling, Q3Sales amounted to 14.09Billion US dollars, representing a 43.8% increase in sales compared to the second quarter.

As ofThe first three quarters of 2023,Mounjaro's sales have reached $2.958 billion, and Eli Lilly and Company also expected Mounjaro's sales to reach $4 billion in 2023.MounjaroIn the sixth quarter after approvalSingle SeasonSales VolumeAlreadyBreaking through one billion dollars,The sales growth rate is also unmatched across the entire innovative drug market.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message to the WeChat Official Account backstage or send a message, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Pro

New Targets, New Technologies, New Therapies

Business Cooperation: 13502093012

Media Cooperation: 15895423126

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.